BACKGROUND:Laparoscopic magnetic sphincter augmentation (MSA) with the LINX device is a promising new therapy for the treatment of gastroesophageal reflux disease (GERD). Initial studies have demonstrated MSA to be safe and effective. However, no direct comparison between MSA and laparoscopic Nissen fundoplication (LNF), the gold standard surgical therapy for GERD, has been performed. METHODS: A single institution, case-control study was conducted of MSA performed from 2012 to 2013 and a cohort of LNF matched for age, gender, and hiatal hernia size. RESULTS:MSA and LNF were both effective treatments for reflux with 75 and 83 % of patients, respectively, reporting resolution of GERD at short-term follow-up. Dysphagia was common following both MSA and LNF, but severe dysphagia requiring endoscopic dilation was more frequent after MSA (50 vs. 0 %, p = 0.01). Need for dilation did not correlate with size of the LINX device or any other examined patient factors. A trend toward decreased adverse GI symptoms of bloating, flatulence, and diarrhea was seen after MSA compared to LNF (0 vs. 33 %). MSA had a shorter operative time (64 vs. 90 min, p < 0.01) but other peri-operative outcomes, including pain, morbidity, and re-admissions were equivalent to LNF. MSA patients were more likely to be self-referred (58 vs. 0 %, p < 0.001). CONCLUSIONS:MSA and LNF are both effective and safe treatments for GERD; however, severe dysphagia requiring endoscopic intervention is more common with MSA. Other adverse GI side effects may be less frequent after MSA. Consideration should be paid to these distinct post-operative symptom profiles when selecting a surgical therapy for reflux disease.
RCT Entities:
BACKGROUND: Laparoscopic magnetic sphincter augmentation (MSA) with the LINX device is a promising new therapy for the treatment of gastroesophageal reflux disease (GERD). Initial studies have demonstrated MSA to be safe and effective. However, no direct comparison between MSA and laparoscopic Nissen fundoplication (LNF), the gold standard surgical therapy for GERD, has been performed. METHODS: A single institution, case-control study was conducted of MSA performed from 2012 to 2013 and a cohort of LNF matched for age, gender, and hiatal hernia size. RESULTS: MSA and LNF were both effective treatments for reflux with 75 and 83 % of patients, respectively, reporting resolution of GERD at short-term follow-up. Dysphagia was common following both MSA and LNF, but severe dysphagia requiring endoscopic dilation was more frequent after MSA (50 vs. 0 %, p = 0.01). Need for dilation did not correlate with size of the LINX device or any other examined patient factors. A trend toward decreased adverse GI symptoms of bloating, flatulence, and diarrhea was seen after MSA compared to LNF (0 vs. 33 %). MSA had a shorter operative time (64 vs. 90 min, p < 0.01) but other peri-operative outcomes, including pain, morbidity, and re-admissions were equivalent to LNF. MSA patients were more likely to be self-referred (58 vs. 0 %, p < 0.001). CONCLUSIONS: MSA and LNF are both effective and safe treatments for GERD; however, severe dysphagia requiring endoscopic intervention is more common with MSA. Other adverse GI side effects may be less frequent after MSA. Consideration should be paid to these distinct post-operative symptom profiles when selecting a surgical therapy for reflux disease.
Authors: Luigi Bonavina; Tom DeMeester; Paul Fockens; Daniel Dunn; Greta Saino; Davide Bona; John Lipham; Willem Bemelman; Robert A Ganz Journal: Ann Surg Date: 2010-11 Impact factor: 12.969
Authors: Brant K Oelschlager; Kevin C Ma; Renato V Soares; Martin I Montenovo; Juan E Munoz Oca; Carlos A Pellegrini Journal: Ann Surg Date: 2012-07 Impact factor: 12.969
Authors: Robert A Ganz; Jeffrey H Peters; Santiago Horgan; Willem A Bemelman; Christy M Dunst; Steven A Edmundowicz; John C Lipham; James D Luketich; W Scott Melvin; Brant K Oelschlager; Steven C Schlack-Haerer; C Daniel Smith; Christopher C Smith; Dan Dunn; Paul A Taiganides Journal: N Engl J Med Date: 2013-02-21 Impact factor: 91.245
Authors: Luigi Bonavina; Greta I Saino; Davide Bona; John Lipham; Robert A Ganz; Daniel Dunn; Tom DeMeester Journal: J Gastrointest Surg Date: 2008-10-10 Impact factor: 3.452
Authors: Leigh A Humphries; Jonathan M Hernandez; Whalen Clark; Kenneth Luberice; Sharona B Ross; Alexander S Rosemurgy Journal: Surg Endosc Date: 2013-03-19 Impact factor: 4.584
Authors: Daniel Skubleny; Noah J Switzer; Jerry Dang; Richdeep S Gill; Xinzhe Shi; Christopher de Gara; Daniel W Birch; Clarence Wong; Matthew M Hutter; Shahzeer Karmali Journal: Surg Endosc Date: 2016-12-15 Impact factor: 4.584